Feature | Cath Lab | September 12, 2017

Cardiovascular Research Foundation Appointed Juan Granada as New President, CEO

Distinguished cardiologist takes the helm of key interventional cardiology organization, sponsor of TCT

Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO). CRF sponsors TCT.

The Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO).


September 12, 2017 – The Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO). Granada was also appointed to CRF’s Board of Directors. A renowned leader in cardiology, he joined CRF in 2007 and served as executive director and chief innovation officer at the CRF Skirball Center for Innovation. He is also an assistant professor of medicine at Columbia University College of Physicians and Surgeons. 

Granada also has served as a member of the Editorial Board for Diagnostic and Interventional Cardiology (DAIC) magazine since 2010.

“Juan’s proven leadership skills, along with his expertise across preclinical, clinical, and educational initiatives will help CRF strengthen and expand its role in the development of innovative new technologies and therapies that will benefit people with heart disease worldwide,” said Eric B. Woldenberg, Esq., chairman of the CRF Board of Directors and a senior partner at Pryor Cashman LLP.

“Since its inception, CRF has played a major role in the rapid progress that has been made in interventional cardiology by establishing the safe use of new technologies and therapies for heart disease,” Granada said. “I am eager to take on this new role and work with my distinguished colleagues to ignite the next wave of innovation that will help doctors save and improve the quality of their patients’ lives.”

“CRF has grown due to a special blend of passion, creativity, and productivity, and Juan embodies our innovative culture,” said Martin B. Leon, M.D., founder and chairman emeritus of CRF and its co-director, medical research and education. “With his unique combination of advanced interventional skills, entrepreneurial spirit, and business insight, he has the visionary capacity to foresee new opportunities. Importantly, Juan is a caring and thoughtful people person who will catalyze communication and collaboration both inside and outside the organization.”

“Juan’s professionalism, creativity and ‘can do’ mindset make him an exceptional individual for this position,” added Gregg W. Stone, M.D., CRF’s co-director of medical research and education. “His knowledge of interventional cardiovascular medicine from bench to bedside coupled with extensive expertise in medical innovation will propel CRF to new levels of achievement in research and education.”

Granada is one of the world’s foremost investigators in the translational validation of novel cardiovascular therapies. He has helped develop and successfully validate several endovascular imaging and device technologies. He received his medical degree from the Institute of Health Sciences in Medellin, Colombia and finished his cardiovascular disease and interventional cardiology fellowships at Baylor College of Medicine in Houston, Texas.  

 

Video and Article Interviews With Dr. Juan Granada:

VIDEO: Bioresorbable Stent Failure Modes, Technique, Patient Selection and Future Development

VIDEO: Transcatheter Mitral Valve Technology, Anatomical Challenges

Advances and Future Directions for Transcatheter Valves

VIDEO: Transcatheter Mitral Valve Therapies in Development — TVT 2015

VIDEO: The Evolution of TAVR Technology — TVT 2015

Transcatheter Mitral Valve Replacement Devices in Development

Drug-eluting Balloons Enter the U.S. Market

Advances in Intravascular Imaging

 

For more information: www.crf.org


Related Content

News | Cardiovascular Business

July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing ...

Home July 29, 2024
Home
News | Cardiovascular Business

July 18, 2024 — Circle Cardiovascular Imaging, a developer of artificial intelligence (AI)-driven cardiovascular imaging ...

Home July 18, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Guidehealth, an artificial intelligence (AI)-enabled healthcare services company, has announced a ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Edwards Lifesciences announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 11, 2024 — Medical device company R3 Vascular Inc., developer of novel, best-in-class bioresorbable scaffolds for ...

Home July 11, 2024
Home
News | Cardiovascular Business

July 9, 2024 — Disparities in cardiovascular disease outcomes between urban and rural areas continue to widen, yet ...

Home July 09, 2024
Home
Feature | Cardiovascular Business

The DAIC team wishes you a safe and happy 4th of July!

Home July 04, 2024
Home
News | Cardiovascular Business

July 3, 2024 — Over the past decade, 342 cardiology clinics have been acquired by private equity firms, with over 94% of ...

Home July 03, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

From FDA approvals to new clinical trials, here is a look at DAIC's top-read content during the month of June: 1 ...

Home July 02, 2024
Home
News | Cardiovascular Business

July 1, 2024 — CVRx, Inc., a commercial-stage medical device company, announced three additions to its senior leadership ...

Home July 01, 2024
Home
Subscribe Now